Press Releases

Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi. On more than 30 pages, the extensive yet small booklet contains all the required product information in more than 20 languages. Accuracy, safety, efficiency and speed are essential to the successful performance of clinical trials. Since most studies are conducted internationally, the investigational

The 13th edition of MEDICAL FAIR ASIA originally scheduled for 9-11 September 2020 will be postponed to the last quarter of the year; 9-11 December 2020. The region’s leading medical and healthcare trade fair focusing on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies is organised by Messe Düsseldorf Asia. Rescheduling the trade fair was necessary in view of the continuing fight against COVID-19 which includes ongoing travel res

Messe Düsseldorf Asia and SPETA (Singapore Precision Engineering and Technology Association), co-organisers of MEDICAL MANUFACTURING ASIA have made the decision to cancel the 2020 edition of the exhibition. It was to be held from 9-11 September 2020 at Marina Bay Sands. MEDICAL MANUFACTURING ASIA - 5th Manufacturing Processes for Medical Technology Exhibition and Conference, is a specialist exhibition for Asia's MedTech and medical manufacturing processes sectors and will n

Bexion Pharmaceuticals, Inc. announced  that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 and 7 years of age. It makes up 10-15% of all brain tumors in children, with about 150-300 new diagnoses per year in the United States. Unfortunately, fewer

Life Science Newswire – Digital Science, a leading technology company serving emergent needs across the research sector, has today released a report highlighting the growth in research around the UN’s Sustainable Development Goals (SDGs). The report Contextualizing Sustainable Development Research, which was produced by Digital Science’s Consultancy Group led by Dr Juergen Wastl, looks at the state of the world’s research on the UN’s SDG’s. It fin

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells), the Company’s lead product candidate for treatment of mucosal pemphigus vulgaris (mPV), for improving healing of mucosal blisters in p

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Heart failure occurs when the heart does not pump enough blood to support the body's needs, and this type of heart failure happens when the heart's main pumping chamber, the left ventricle, is weakened. With the approval, Farxiga is the first in this part

Today, Samplix launched its comprehensive service program to grant any laboratory access to the advantages of Xdrop™ technology. By partnering with the Samplix Service Team, researchers can leverage the unique Xdrop™ approach to address complex genomic questions, including gap closing, sequencing of repeat elements, detecting viral insertion sites, revealing unintended CRISPR edits, and more. Xdrop™ is Samplix’ proprietary technology to enrich genomic regions

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 corona

Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators. COVID-19 patients on prolonged mechanical ventilation in the intensi